Primary tabs

Needle-free Vaccination via Nanoparticle Aerosols

Vaccine delivery systems that target specific areas of the body have the potential to be especially effective against some types of infection. For example, inhaled vaccines may better guard against respiratory diseases, such as tuberculosis, and those that commonly infect the tissues of the nose and throat, such as diphtheria. Dr. Edwards is leading a multidisciplinary team using materials science technologies combined with infectious disease, device, and toxicology expertise to reformulate tuberculosis and diphtheria vaccines into aerosol sprays that can be inhaled. The team's ultimate objective is to develop a cell-based BCG vaccine for tuberculosis and a protein antigen CRM 197 vaccine for diphtheria in the form of novel porous nanoparticle aggregate (PNAP) aerosols.

Grant ID
OPP37867
Show on Hub
On
Show on Spoke
On
Follow-on Funding
Off
Lead Funding Organization
Initiatives
Principal Investigator
Individual Funder Information
Funding Organization
Funding Amount (in original currency)
7600000.00
Funding Currency
USD
Funding Amount (in USD)
7600000.00
Project Primary Sector
Funding Date Range
-
Funding Total (In US dollars)
7600000.00
Co-Funded
False